Description

(-)-Treprostinil is a potent, long-acting prostacyclin (PGI2) analog and vasodilator, representing a high-purity active pharmaceutical ingredient (API) of significant therapeutic value. Its primary commercial importance lies in its critical role in the formulation of treatments for pulmonary arterial hypertension (PAH), where it helps to reduce vascular resistance and improve exercise capacity. This compound is essential for pharmaceutical manufacturers and research institutions engaged in the development and production of advanced cardiovascular therapies, including injectable solutions and inhalation formulations.

Application

• Pharmaceutical API: Primary active ingredient in approved medications for the treatment of pulmonary arterial hypertension (PAH).
• Injectable Formulations: Used in the manufacture of sterile, parenteral solutions for continuous subcutaneous or intravenous infusion.
• Inhalation Therapy: Key component in nebulized solutions for targeted pulmonary delivery.
• Research & Development: Reference standard and building block in preclinical and clinical studies for cardiovascular and pulmonary diseases.
• Drug Delivery Systems: Investigational use in developing sustained-release and novel delivery platforms.
• Bioscience Research: Tool compound for studying prostacyclin receptor (IP receptor) signaling pathways and vascular biology.

Basic Information

Product Name	(-)-Treprostinil
CAS No.	112421-28-0
Molecular Formula	C23H34O5
Molecular Weight	390.51 g/mol
Synonyms	Treprostinil; UT-15; (+)-(1R,2R,3aS,9aS)-[[2,3,3a,4,9,9a-Hexahydro-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-1H-benz[f]inden-5-yl]oxy]acetic acid; UNII-4A9OS9AQ71; 15-epi-Treprostinil; Remodulin (brand name); Tyvaso (brand name); Orenitram (brand name)
EINECS	Contact for details

Quality Control

Our (-)-Treprostinil is manufactured under strict quality systems designed for pharmaceutical active ingredients. Each batch is subjected to comprehensive analytical testing, including chiral purity verification, to ensure it meets stringent specifications for identity, potency, and purity. A detailed Certificate of Analysis (COA) is provided with each shipment, documenting compliance with relevant pharmacopeial standards (e.g., USP monographs) and internal specifications. Our quality commitment supports regulatory filings and ensures supply chain reliability for critical drug production.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C) or as specified on the label. This material is hygroscopic (moisture-sensitive) and must be kept under inert conditions or in a desiccated environment to maintain stability and prevent degradation.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to reference standard
Identification (HPLC)	Retention time corresponds to reference
Assay (HPLC)	≥ 98.5%
Chiral Purity (HPLC)	≥ 99.0%
Related Substances (HPLC)	Individual impurity: ≤ 0.5% Total impurities: ≤ 1.5%
Residual Solvents (GC)	Complies with ICH Q3C
Water Content (KF)	≤ 1.0%
Residue on Ignition	≤ 0.1%
Heavy Metals	≤ 20 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.